BREAST LOBULAR CARCINOMA IN SITU
Clinical trials for BREAST LOBULAR CARCINOMA IN SITU explained in plain language.
Never miss a new study
Get alerted when new BREAST LOBULAR CARCINOMA IN SITU trials appear
Sign up with your email to follow new studies for BREAST LOBULAR CARCINOMA IN SITU, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for chemo-resistant breast cancer? trial tests immune-boosting drug
Disease control TerminatedThis study looked at whether the drug abemaciclib could help people with triple negative breast cancer that didn't respond to standard chemotherapy. The goal was to see if the drug could change the tumor's immune environment to make it more attackable by the body's defenses. The …
Matched conditions: BREAST LOBULAR CARCINOMA IN SITU
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 10, 2026 13:27 UTC
-
Breast cancer prevention study halted early: tamoxifen pill vs. gel
Prevention TerminatedThis study tested whether a tamoxifen gel applied to the skin works as well as the pill form to lower breast cancer risk in women with atypical hyperplasia or lobular carcinoma in situ (LCIS). About 65 women were expected to join, but the study was stopped early. The goal was to …
Matched conditions: BREAST LOBULAR CARCINOMA IN SITU
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Prevention
Last updated Jun 12, 2026 12:06 UTC
-
Genetic test may help minority women navigate breast cancer risk
Knowledge-focused TerminatedThis study looked at whether adding a polygenic risk score (a genetic test) to standard breast cancer risk tools helps African American and Hispanic women make better decisions about extra screening or prevention. The study enrolled 19 women at high risk for breast cancer. The go…
Matched conditions: BREAST LOBULAR CARCINOMA IN SITU
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 10, 2026 13:27 UTC